

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

**2nd Current Challenges, Controversies and Consensus in Oncology
(2nd C4 National Conference)**

**Program Directors - Dr K. Pavan Raghava Reddy & Dr S. Krupa Shankar
10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur**

Day 1 | 10th January, 2026 | Saturday

9:00 am to 9:05 am	Welcome Address	
9:05 am to 9:50 am	Academic Session 1 - Head and Neck Oncology Chairpersons: Dr. T. V. Sivaramakrishna & Dr. Subbarayudu Yarlagadda	
9:05 - 9:10	NIVOPOSTOP (GORTEC 2018-01) and KEYNOTE-689 trials: Role of adjuvant immunotherapy in resectable HNSCC	Dr. Sravan Kumar Bodepudi
9:10 - 9:15	PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial.	Dr. Haneesha Polavarapu
9:15 - 9:20	Clinical Benefit and Safety of Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma: The UPGRADE-RT Multicenter Randomized Controlled Trial/DESCALATE RTOG trials for HPV	Dr. K. Sudhakar Kotlapati
9:20 - 9:25	Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study)	Dr. Archit Joshi
9:25 - 9:50	Panel Discussion Moderator: Dr. Krishna Prasad Panelists: Dr. Satheesh Kumar D, Dr. K. S. Abhishek Raghava, Dr. N. V. S. Praveen, Dr. Sravan Kumar Bodepudi, Dr. K. Sudhakar Kotlapati & Dr. Archit Joshi	
9:50 am to 10:10 am	Sponsored Session (Roche) Improving OS and QoL: Maximising Patient Outcomes in unresectable Hepatocellular Carcinoma Speaker: Dr. Sreekanth Boga	
10:10 am to 10:55 am	Academic Session 2 - Genito-Urinary Oncology Chairpersons: Dr. N. Subba Rao & Dr. P. T. Ravi Chander	
10:10 - 10:15	Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (MCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.	Dr. Bhaskar Bhuvan

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

10:15 - 10:20	RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse	Dr. Satheesh Kumar D
10:20 - 10:25	IMvigor011: A Phase 3 Trial of ctDNA-Guided Adjuvant Atezolizumab versus Placebo in MIBC (ESMO 2025)	Dr. Sreekanth Boga
10:25 - 10:30	EPIC-A: Phase II trial of cemiplimab plus standard of care chemotherapy followed by maintenance cemiplimab in locally advanced or metastatic penile carcinoma.	Dr. Ashwin Oommen Philips
10:30 - 10:55	Panel Discussion Moderator: Dr. Senthil Rajappa Panelists: Dr. Sreekanth Boga, Dr. Murali Nalabotu, Dr. Bhaskar Bhuvan, Dr. Satheesh Kumar D, Dr. Palukuri Nageswara Reddy & Dr. Ashwin Oommen Philips	
10:55 am to 11:25 am	Sponsored Session (Astellas) Enfortumab Vedotin in Relapsed Refractory Bladder Cancer + Panel Discussion Moderator: Dr. Senthil Rajappa Panelists: Dr. Ram Prahlad, Dr. Kolluru Sai Krishna & Dr. Satya Srinivas	
11:30 am to 12:00 pm	Inauguration Lighting the lamp: Dr. S G Ramanan Inaugural Address: Prof. Purvish Parikh	
12:00 pm to 12:20 pm	Sponsored Session (Johnson & Johnson) A tale of 2 stories: Redefining treatment outcomes with mariposa-2 and papillon Speaker: Dr. Sravan Kumar Bodepudi	
12:20 pm to 12:45 pm	Keynote Lecture Challenges and Solutions to Cervical Cancer Screening and Vaccination - Our Experience Dr. Raghunadharao Digumarti	
12:45 pm to 2:00 pm	Lunch	
2:00 pm onwards	PG QUIZ SESSION (Preliminary)	
2:00 pm to 2:45 pm	Academic Session 3 - Gynae Oncology Chairpersons: Dr. S G Ramanan & Dr. Aruna Vemu	
2:00 - 2:05	ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72)	Dr. Harshvardhan Atreya
2:05 - 2:10	Sentinel lymph node biopsy versus pelvic lymphadenectomy in cervical cancer: The PHENIX trial.	Dr. Kalyan Chakradhar Polavarapu
2:10 - 2:15	AtTEnd (LBA40): Phase 3, double-blind, randomized, placebo-controlled clinical trial of adding atezolizumab to standard chemotherapy for	Dr. Hemanth Muthuluri

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

	advanced or recurrent endometrial cancer (the role of Aneuploidy Score as a potential predictive biomarker in MMRd endometrial cancer)	
2:15 - 2:20	TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).	Dr. G Muralidhar
2:20 - 2:45	Panel Discussion Moderator: Dr. Vijay G Panelists: Dr. Kolluru Sai Krishna, Dr. Sindhu Kilaru, Dr. Aditya Nadella, Dr. Harshvardhan Atreya, Dr. Kalyan Chakradhar Polavarapu, Dr. Hemanth Muthuluri & Dr. G Muralidhar	
2:55 pm to 3:15 pm	Sponsored Session (Roche) Role of Tecentriq in first line patients with advanced NSCLC not eligible for a platinum containing regimen Speaker: Dr. P Nageswara Reddy	
3:25 pm to 3:45 pm	Sponsored Session (Intas) (HETRONIFLY) Serplulimab: New Standard of Care in Lung Cancer Moderator: Dr. Satya Srinivas Appala Panelists: Dr. Sreekanth Boga, Dr. Aditya Nadella, Dr. Matta Venkata Raviteja, Dr. Kolluru Sai Krishna, Dr. Minu Chandra & Dr. Hemanth Makineni	
3:45 pm to 4:00 pm	Tea Break	
4:00 pm to 4:45 pm	Academic Session 4 - Thoracic Oncology Chairpersons: Dr. Trivadi Sundaram Ganesan & Dr. Ramakrishna Rachakonda	
4:00 - 4:05	Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial	Dr. Nagender Sharma
4:05 - 4:10	HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR-mutated NSCLC after a third-generation EGFR TKI	Dr. Saju SV
4:10 - 4:15	Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study.	Dr. Sumant Gupta
4:15 - 4:20	Randomized trial of relevance of time-of-day of immunochemotherapy for progression-free and overall survival in patients with non-small cell lung cancer (ASCO 2025)	Dr. Kiran Kumar DVS
4:20 - 4:45	Panel Discussion Moderator: Dr. S. Krupa Shankar Panelists: Dr. Balabhadra Prabhakara Vijayasarithi, Dr. Matta Venkata Raviteja, Dr. Nagender Sharma, Dr. Saju SV, Dr. Sumant Gupta & Dr. Kiran Kumar DVS	

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

<p>4:45 pm to 5:05 pm</p>	<p>Sponsored Session (AstraZeneca) Revolutionizing Treatment for HER2+ IHC 3+ Solid Tumors with ENHERTU Speaker: Dr. Satya Srinivas Appala</p>
<p>5:05 pm to 5:25 pm</p>	<p>Sponsored Session (AstraZeneca) Extending benefit in EGFRm NSCLC: The power of combinations Speaker: Dr. Sreekanth Boga</p>
<p>5:25 pm to 6:05 pm</p>	<p>Sponsored Session (Bristol Myers Squibb) Navigating the Treatment Options in 1st Line – Gastric, GE Junction & Esophageal Cancer Moderator: Dr. Sumant Gupta Panelists: Dr. Satya Srinivas Appala, Dr. Ram Prahlad, Dr. Sreekanth Boga & Dr. Kolluru Sai Krishna</p>
<p>6:10 pm to 6:30 pm</p>	<p>Sponsored Session (MSD) Evolving Paradigms in Gastric Cancer from Evidence to Clinical Practice Speaker: Dr. Sreekanth Boga</p>

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

Day 2 | 11th January, 2026 | Sunday

Day 2 11 th January, 2026 Sunday		
9:00 am to 9:45 am	Academic Session 5 - GI/HPB Oncology Chairpersons: Dr. Anita Ramesh & Dr. Vishnu Prasad Ravella	
9:00 - 9:05	Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (DMMR) colon cancer (Alliance A021502; ATOMIC).	Dr. Venkatesh K
9:05 - 9:10	Results of a randomized phase III trial of pre-operative chemotherapy with MFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (ASCO 2025) CASSANDRA trial	Dr. Siva Prasad
9:10 - 9:15	A phase III randomized clinical trial evaluating perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLCAGB)	Dr. Krishna Chaitanya
9:15 - 9:20	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone followed by adjuvant therapy in biliary tract cancer: Final results from the phase III AIO/CALGP/ACO-GAIN-Trial.	Dr. Prathap Avvaru
9:20 - 9:45	Panel Discussion Moderator: Dr. Palanki Satya Dattatreya Panelists: Dr. Y Ramakrishna Reddy, Dr. Pothala Vijaya Lakshmi, Dr. Minu Chandra, Dr. Venkatesh K, Dr. Siva Prasad, Dr. Prathap Avvaru & Dr. Krishna Chaitanya	
9:55 am to 10:50 am	Academic Session 6 - Hematology Chairpersons: Dr. Sachin Jadhav & Dr. Pavan Kumar Boyella	
9:55 - 10:00	POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Dr. Rakesh Reddy Boya
10:00 - 10:05	Randomized, multi-center study of carfilzomib, lenalidomide, and dexamethasone (KRD) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM): The ADVANCE clinical trial.	Dr. Ramavath Dev
10:05 - 10:10	Asciminib in Newly Diagnosed Chronic Myeloid Leukemia (ASC4FIRST trial)	Dr. Jayachandran P K
10:10 - 10:15	Results from PARADIGM — a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia	Dr. Vasu Babu Goli
10:15 - 10:50	Panel Discussion Moderator: Dr. Ganesh Jaishetwar Panelists: Dr. Amarnadh Polisetty, Dr. Rajiv Mohan Nannapaneni, Dr. Rakesh Reddy Boya, Dr. Ramavath Dev, Dr. Jayachandran P K, Dr. Ramu Kandula & Dr. Vasu Babu Goli	
10:50 am to 11:00 am	Tea Break	

10th & 11th January, 2026 | Welcomhotel By ITC Hotels Guntur

11:00 am to 11:25 am	Keynote Lecture Epithelial Ovaian Cancer: Our Experience and Lessons Learnt Dr. Lalit Kumar	
11:30 am to 12:15 pm	Academic Session 7 - Breast Oncology Chairpersons: Dr. Krishna Reddy G & Dr. Sreekanth Kotagiri	
11:30 - 11:35	T-DXd + pertuzumab vs taxane + THP for first-line treatment of patients with HER2+ advanced/metastatic breast cancer: DESTINY-Breast09 trial	Dr. Sainath Bhethanabhotla
11:35 - 11:40	Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial.	Dr. Palukuri Nageswara Reddy
11:40 - 11:45	Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1-positive advanced triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study.	Dr. Pydi Venkateswar Rao
11:45 - 11:50	Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer: INAVO120 trial	Dr. Aditya Pavan Kumar
11:50 - 12:15	Panel Discussion Moderator: Dr. N Aditya Murali Panelists: Dr. V Ravi Teja Cherukuri, Dr. Pamidi Kavya Siva Keerthana, Dr. Satya Srinivas Appala, Dr. Sainath Bhethanabhotla, Dr. Palukuri Nageswara Reddy, Dr. Pydi Venkateswar Rao & Dr. Aditya Pavan Kumar	
12:15 pm to 12:35 pm	PG QUIZ Final	
12:35 pm to 12:50 pm	PG Oral Presentation	
12:50 pm to 1:10 pm	Sponsored Session (MSD) Cervical Cancer – The Evolving Role of Immunotherapy in the Locally Advanced Cervical Cancer Speaker: Dr. Ramavath Dev	
1:10 pm to 1:30 pm	Sponsored Session (MSD) Role of Immunotherapy and Its Sequencing Strategy in Advanced Triple Negative Breast Cancer Speaker: Dr. Venkatesh K	
1:30 pm to 1:40 pm	PG Prize Distribution	
1:40 pm to 1:50 pm	Vote of Thanks followed by Lunch	